Invitae Hereditary Breast and Gyn Cancers Guidelines-Based Panel
Use
The Invitae Hereditary Breast and Gyn Cancers Guidelines-Based Panel analyzes genes associated with a predisposition to adult-onset breast, ovarian, uterine, fallopian tube, and peritoneal cancers. It is designed to help guide cancer screening and risk-reduction measures by providing medically actionable, evidence-based management options. The test can define screening initiation age, test intervals, methodology used, and preventive options, which may prevent cancer or lead to earlier diagnosis, increasing chances of successful treatment and survival.
Special Instructions
This test is specifically for heritable germline mutations, not for detecting somatic mutations in tumor tissue. Any analysis limitations will be noted in the report. Clients can request a specimen collection kit and contact client services for questions.
Limitations
The test covers clinically important regions of each gene, including select non-coding variants, but does not analyze regions outside these. Structural rearrangements, such as inversions and translocations, may not be detected. Certain details about variants, like mosaicism or mapping ambiguity, may not be resolved. Sequence changes in promoters and non-coding regions are generally not covered unless explicitly noted. In rare cases, the DNA analyzed may not represent the patient’s constitutional genome due to conditions like circulating hematolymphoid neoplasm or recent blood transfusion.
New York Approved
Methodology
NGS (Targeted)
Biomarkers
Result Turnaround Time
10-21 days
Related Documents
For more information, please review the documents below
Specimen
Whole Blood
Volume
3mL
Minimum Volume
Not provided
Container
purple-top EDTA tube (K2EDTA or K3EDTA)